The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Nelson Cox - Lake Street Capital Markets LLC - Analyst
: This is Nelson Cox on for Frank. Congrats on all the progress here. I want to start with 2026. I understand you guys are not guiding for that today,
but just any color you feel comfortable providing there in terms of how we should be thinking about growth in 2026. When I look at kind of where
the Street is at, there's kind of a wide range.
So just wanted to give a chance if you guys are comfortable to provide more color there.
Question: Nelson Cox - Lake Street Capital Markets LLC - Analyst
: All right. Fair enough. And then -- kind of curious if there's any additional color you can provide outside of liver in terms of growth you're seeing
in your other indications.
Question: Matthew Park - Cantor Fitzgerald LP - Analyst
: This is Matthew Park on for Ross today. I guess just starting off, as you initiate the genicular artery embolization study for knee GAE, I guess, how
do you view the broader competitive landscape developing around here? And where would you see TriNav fitting in within the potential standard
of care?
Question: Matthew Park - Cantor Fitzgerald LP - Analyst
: Got it. That's super helpful color. And then maybe one for David. So on gross margins, you called out some headwinds in the quarter driven by
these newly launched products. I guess how should we think about the cadence of gross margin over the next couple of quarters and when you
would kind of expect these manufacturing efficiencies to come back in?
Question: Carl Byrnes - Northland Securities Inc - Analyst
: Congratulations on your progress. Going back to TARE mapping, what have you experienced with respect to conversion of existing TARE users
with TriNav to mapping? Is it -- I know you mentioned that there's some education process around the new HCPCS code, the C8004 code. Are you
-- can you quant that at all? I know you quanted the revenue growth of 30% for mapping, but do you have any feel there?.
Question: Carl Byrnes - Northland Securities Inc - Analyst
: Great. Very helpful. And then just one quick follow-up. What are you seeing with respect to adoption of LV and FLX and in what procedure specifically?
Question: Shaymus Contorno, CFA - Oppenheimer & Co Inc - Analyst
: This is Shaymus on for Suraj. Just one from our end, but just trying to cut this, I guess, two different ways. So how has kind of growth/utilization
look for accounts that launched, say, 18 months ago versus one year ago versus six months? How kind of -- has the ramp kind of been increasing
over time? And I guess, could you kind of quantify that?
And then on a separate note, again, on utilization, how does utilization for a physician that's added on with an existing account look over time?
| 
